1. Home
  2. CRNC vs LRMR Comparison

CRNC vs LRMR Comparison

Compare CRNC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cerence Inc.

CRNC

Cerence Inc.

HOLD

Current Price

$12.78

Market Cap

362.2M

Sector

Technology

ML Signal

HOLD

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

HOLD

Current Price

$3.71

Market Cap

332.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNC
LRMR
Founded
2020
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
362.2M
332.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CRNC
LRMR
Price
$12.78
$3.71
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$11.50
$16.71
AVG Volume (30 Days)
2.0M
1.5M
Earning Date
11-19-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$251,781,000.00
N/A
Revenue This Year
$27.55
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.94
$1.61
52 Week High
$27.50
$6.91

Technical Indicators

Market Signals
Indicator
CRNC
LRMR
Relative Strength Index (RSI) 66.43 51.60
Support Level $9.56 $3.12
Resistance Level $11.08 $3.69
Average True Range (ATR) 0.78 0.27
MACD 0.45 0.04
Stochastic Oscillator 92.64 84.56

Price Performance

Historical Comparison
CRNC
LRMR

About CRNC Cerence Inc.

Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: